The clinical pharmacology of mexiletine.
作者信息
Campbell N P, Kelly J G, Adgey A A, Shanks R G
出版信息
Br J Clin Pharmacol. 1978 Aug;6(2):103-8. doi: 10.1111/j.1365-2125.1978.tb00833.x.
Abstract
- Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2. There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3. The mean volume of distribution was 6.63 l/kg. The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4. Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective. Within this therapeutic range severe side effects were uncommon. 5. Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.
摘要
相似文献
1
The clinical pharmacology of mexiletine.
Br J Clin Pharmacol. 1978 Aug;6(2):103-8. doi: 10.1111/j.1365-2125.1978.tb00833.x.
2
Plasma mexiletine concentrations following combined oral and intramuscular administration.
Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.
3
Dose independent pharmacokinetics of mexiletine in healthy volunteers.
Br J Clin Pharmacol. 1986 Mar;21(3):319-21. doi: 10.1111/j.1365-2125.1986.tb05196.x.
4
Mexiletine in normal volunteers.
Br J Clin Pharmacol. 1978 Oct;6(4):372-3. doi: 10.1111/j.1365-2125.1978.tb00868.x.
5
Pharmacokinetics of mexiletine in renal insufficiency.
Acta Cardiol Suppl. 1980(25):55-65.
6
A schedule for combined intravenous and oral dosing with mexiletine.
J Int Med Res. 1979;7(2):162-4. doi: 10.1177/030006057900700209.
7
Adaptation of the dose of mexiletine according to pharmacokinetic data.
Acta Cardiol Suppl. 1980(25):67-73.
8
Mexiletine in the management of ventricular dysrhythmias.
Eur J Cardiol. 1977 Dec;6(4):245-58.
9
[Kinetics of mexiletine distribution in the rat].
Arch Farmacol Toxicol. 1983 Apr;9(1):65-76.
10
Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine.
Postgrad Med J. 1977;53 Suppl 1:128-33.
引用本文的文献
1
Human-induced pluripotent stem cell-derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs.
Pharmacol Res Perspect. 2021 Aug;9(4):e00828. doi: 10.1002/prp2.828.
2
Interactions of Mexiletine with Novel Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis.
Neurochem Res. 2018 Oct;43(10):1887-1896. doi: 10.1007/s11064-018-2606-8. Epub 2018 Aug 16.
3
Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.
Pharmacol Res Perspect. 2015 Oct;3(5):e00160. doi: 10.1002/prp2.160. Epub 2015 Jul 31.
4
Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.
Br J Pharmacol. 2006 Oct;149(3):300-10. doi: 10.1038/sj.bjp.0706867. Epub 2006 Aug 21.
5
Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.
Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9. doi: 10.1007/s00228-003-0656-5. Epub 2003 Aug 23.
6
Therapeutic drug monitoring of antiarrhythmic drugs.
Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.
7
Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.
Br J Clin Pharmacol. 2001 Jul;52(1):100-3. doi: 10.1046/j.0306-5251.2001.01411.x.
8
Clinical pharmacokinetics of mexiletine.
Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.
9
Involvement of CYP1A2 in mexiletine metabolism.
Br J Clin Pharmacol. 1998 Jul;46(1):55-62. doi: 10.1046/j.1365-2125.1998.00048.x.
10
Plasma mexiletine concentrations following combined oral and intramuscular administration.
Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.
本文引用的文献
1
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.
J Pharm Pharmacol. 1973 Jul;25(7):550-3. doi: 10.1111/j.2042-7158.1973.tb09155.x.
2
St-segment displacement and early hospital discharge in acute myocardial infarction.
Lancet. 1973 Dec 8;2(7841):1284-8. doi: 10.1016/s0140-6736(73)92868-7.
3
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.
Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.
4
Treatment of ventricular arrhythmias with mexiletine (Kö 1173).
Lancet. 1973 Aug 25;2(7826):399-404. doi: 10.1016/s0140-6736(73)92270-8.
5
Drug therapy. Clinical Pharmacokinetics (first of two parts).
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.
6
Absorption, distribution and elimination of mexiletine.
Postgrad Med J. 1977;53 Suppl 1:50-5.
7
Measurement of plasma mexiletine concentrations.
Postgrad Med J. 1977;53 Suppl 1:48-9.
8
Oral dosage schedules for mexiletine.
Postgrad Med J. 1977;53 Suppl 1:155-7.
9
Long-term treatment of ventricular arrhythmias with oral mexiletine.
Am Heart J. 1976 Jan;91(1):58-65. doi: 10.1016/s0002-8703(76)80435-8.
10
Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
Lancet. 1975 Jun 7;1(7919):1257-60. doi: 10.1016/s0140-6736(75)92548-9.
Zotero 插件